Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 246
Filtrar
2.
Am J Clin Oncol ; 47(7): 305-310, 2024 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-38421015

RESUMEN

OBJECTIVE: There is an inverse relationship between cancer cure and overall treatment time (OTT) in patients treated with surgical resection and radiotherapy (RT). METHODS: OTT was evaluated based on the reconstruction procedure in 420 patients with oral cavity and larynx cancers treated with surgery and RT between 1991 and 2020. RESULTS: With OTT >85 days, the difference between no versus yes flap reconstruction was ~20 percentage points and significant for all comparisons: primary closure (+/- skin graft), 49%, vs. rotation or free flap, 71% ( P <0.0001); primary closure (+/- skin graft), 49%, versus free flap without bone, 66% ( P =0.0358); and primary closure (+/- skin graft), 49%, versus free flap with bone, 82% ( P <0.0001). CONCLUSIONS: The use of flap reconstructions results in substantial increases in OTT. Findings suggest a need to reevaluate current policies regarding the choice of reconstruction and starting RT sooner after surgery.


Asunto(s)
Neoplasias Laríngeas , Neoplasias de la Boca , Procedimientos de Cirugía Plástica , Humanos , Masculino , Femenino , Persona de Mediana Edad , Neoplasias de la Boca/radioterapia , Neoplasias de la Boca/cirugía , Neoplasias de la Boca/patología , Procedimientos de Cirugía Plástica/métodos , Radioterapia Adyuvante , Neoplasias Laríngeas/radioterapia , Neoplasias Laríngeas/cirugía , Neoplasias Laríngeas/patología , Anciano , Estudios Retrospectivos , Colgajos Quirúrgicos , Adulto , Anciano de 80 o más Años , Factores de Tiempo , Colgajos Tisulares Libres
3.
Am J Clin Oncol ; 47(3): 110-114, 2024 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-37981700

RESUMEN

OBJECTIVE: The safety of single-treatment stereotactic radiosurgery (SRS) for vestibular schwannoma (VS) with radiographic evidence of brainstem compression but without motor deficit is controversial. Data on linear accelerator (linac)-based SRS in this setting are scarce. We address this with an outcomes report from an unselected series of patients with VS with radiographic brainstem compression treated with linac SRS. METHODS: We included 139 patients with unilateral VS (any size) with radiographic brainstem compression (all without serious brainstem neurological deficits). The SRS prescription dose was 12.5 Gy (single fraction) using 6MV linac-produced photon beams, delivered with a multiple arc technique. Inclusion criteria required at least 1 year of radiographic follow-up with magnetic resonance imaging. The primary endpoint was freedom from serious brainstem toxicity (≥grade 3 Common Terminology Criteria for Adverse Events v5); the secondary was freedom from enlargement (tumor progression or any requiring intervention). We assessed serious cranial nerve complications, excluding hearing loss, defined as Common Terminology Criteria for Adverse Events v5 grade 3 toxicity. RESULTS: Median magnetic resonance imaging follow-up time was 5 years, and median tumor size was 2.5 cm in greatest axial dimension and 5 ml in volume. The median brainstem D0.03 ml=12.6 Gy and median brainstem V10 Gy=0.4 ml. At 5 years, the actuarial freedom from serious brainstem toxicity was 100%, and freedom from tumor enlargement (requiring surgery and/or due to progression) was 90%. Severe facial nerve damage in patients without tumor enlargement was 0.9%. CONCLUSION: Linac-based SRS, as delivered in our series for VS with radiographic brainstem compression, is safe and effective.


Asunto(s)
Neuroma Acústico , Radiocirugia , Humanos , Neuroma Acústico/diagnóstico por imagen , Neuroma Acústico/radioterapia , Neuroma Acústico/etiología , Resultado del Tratamiento , Radiocirugia/efectos adversos , Radiocirugia/métodos , Tronco Encefálico/diagnóstico por imagen , Tronco Encefálico/patología , Estudios de Seguimiento , Estudios Retrospectivos
6.
Pract Radiat Oncol ; 13(4): 273-275, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37391234
8.
Am J Clin Oncol ; 46(2): 45-49, 2023 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-36468664

RESUMEN

OBJECTIVE: To report the percentage of resident graduates in the modern era who establish careers in academic radiation oncology 5 to 10 years after residency. MATERIALS AND METHODS: The study population included 1147 radiation oncologists who completed residency between 2011 and 2017 and were practicing radiation oncologists in 2021. RESULTS: The percentage of 2011-2017 graduates with an academic career in 2021 (5 to 10 y after residency): Holman Pathway resident: Yes, 74% versus No, 43% ( P <0.05); PhD degree before residency: Yes, 67% versus No, 38% ( P <0.05), Doximity top-10 ranked residency program: Yes, 66% versus No, 37% ( P <0.05).Logistic regression multivariate analysis confirmed PhD and Doximity top-10 as strong independent predictors for all endpoints.Regarding gender, no significant differences were observed for all 4 endpoints in the percentage of women versus men establishing academic careers at the 5-year to 10-year post-residency time point. CONCLUSION: Since 2011, at least one-third (~35%) of radiation oncology residents have gone into academic medicine and are academically productive 5 to 10 years after residency. Holman Pathway, PhD degree, or Doximity top-10 residency program approximately doubles the probability of an academic career. Moreover, radiation oncology is on track to achieve gender equity in academic medicine.


Asunto(s)
Internado y Residencia , Oncología por Radiación , Masculino , Humanos , Femenino , Oncología por Radiación/educación , Selección de Profesión , Eficiencia , Oncólogos de Radiación
9.
Rep Pract Oncol Radiother ; 27(4): 655-658, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36196424

RESUMEN

Background: Data are scarce on the efficacy of a second radiosurgery (SRS) treatment of vestibular schwannoma that has progressed following initial treatment with SRS. We sought to report the outcome of our repeat SRS series with long-term imaging follow-up. Materials and methods: We retrospectively analyzed 6 patients who met the following criteria: Repeat SRS at our institution between 1995 and 2018; solitary unilateral tumor; no evidence of neurofibromatosis; and magnetic resonance (MR) planning for both SRS treatments. All treatments were delivered with a linear accelerator-based system using head frame immobilization. The prescribed dose to the periphery of the tumor was 12.5 Gy in all initial and repeat SRS treatments, except for one repeat treatment to 10 Gy. Results: Follow-up with MR scan following the second SRS treatment was a median 8.4 years. The tumor control rate (lack of progression) following the second SRS treatment was 83% (5/6). Actuarial 10-year outcomes following repeat SRS were: tumor control, 80%; absolute survival, 80%; and cause-specific survival, 100%. Of the patients with at least minimal hearing retention before initial SRS, none had ipsilateral hearing preservation after initial radiation treatment. Improvement in any pretreatment cranial nerve deficits was not seen. The only permanent grade ≥ 3 toxicity from repeat SRS was a case of infraorbital nerve deficit. No patient developed a stroke, malignant transformation, induced second tumor, or facial nerve deficit. Conclusion: There was excellent overall survival, tumor control, and low morbidity in our series for recurrent vestibular schwannoma submitted to repeat single-fraction SRS, supporting additional studies of this treatment strategy.

10.
Head Neck ; 44(11): 2513-2521, 2022 11.
Artículo en Inglés | MEDLINE | ID: mdl-35950338

RESUMEN

BACKGROUND: We report outcomes among patients with T2 and select T3 glottic squamous cell carcinoma (SCC) treated with radiotherapy. METHODS: We reviewed T2 and T3 (only paraglottic space invasion) N0 M0 glottic SCC patients treated with curative-intent hypofractionated larynx radiotherapy, with or without concurrent systemic therapy. RESULTS: Of 71 patients, those who received concurrent chemotherapy (23/71; 32%) had worse prognostic factors, including impaired cord mobility (70% vs. 40%, p = 0.02) and larger median gross tumor volume (3.0 vs. 1.6 cm3 , p = 0.003). Over a median follow-up of 3.8 years, 2-year local control among patients with impaired cord mobility appeared higher for those who received chemotherapy (88% vs. 61%, p = 0.12), but the difference was not statistically significant. Acute and late toxicity rates were not higher among patients who received chemotherapy. CONCLUSIONS: The addition of concurrent platinum-based chemotherapy to hypofractionated larynx radiotherapy among patients with early-stage glottic SCC with impaired cord mobility appears safe and worthy of additional investigation.


Asunto(s)
Neoplasias Laríngeas , Laringe , Glotis/patología , Humanos , Neoplasias Laríngeas/patología , Laringe/patología , Hipofraccionamiento de la Dosis de Radiación , Pliegues Vocales/patología
12.
Pract Radiat Oncol ; 12(5): 392-396, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35513255

RESUMEN

The risk of serious esophageal damage from stereotactic body radiation therapy for a spine metastasis increases when the target is in the upper thoracic or cervical spine because the esophagus almost touches the anterior edge of the vertebral body at these levels. This report describes a case of severe esophageal damage from stereotactic body radiation therapy to the T-2 vertebral body, reviews pertinent literature, and suggests implications for future research and practice.


Asunto(s)
Radiocirugia , Neoplasias de la Columna Vertebral , Vértebras Cervicales , Esófago , Humanos , Radiocirugia/efectos adversos , Neoplasias de la Columna Vertebral/secundario
13.
Rep Pract Oncol Radiother ; 27(1): 121-124, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35402034

RESUMEN

Background: In patients with well-differentiated thyroid cancer, there is controversy about the prognostic importance of a large number of positive neck nodes and the potential value of radioiodine therapy. The purpose of this study was to evaluate this issue in the group of patients for whom it is most clinically important - those with classic histology and favorable T and M stage. Materials and methods: Twenty-five patients met the following inclusion criteria: classic histology of papillary or follicular thyroid carcinoma treated with total thyroidectomy and neck dissection followed by adjuvant I-131 treatment in our department between January 1, 2003, and December 31, 2013; adult age of > 21 years; and American Joint Committee on Cancer (AJCC ) stage (8th edition) of T0-3, N1b with ≥ 5 positive nodes, and M0. Results: The median positive node number was 10 (range, 5-31). The median adjuvant I-131 dose was 158 mCi (range, 150-219 mCi). The median follow-up in patients without recurrence after treatment was 7.3 years. The 10-year actuarial rates were favorable: overall survival, 100%; freedom from visible recurrence, 82%; and visible or biochemical recurrence, 72%. Conclusion: Recurrence was infrequent in our study population with ≥ 5 positive nodes following moderate-dose adjuvant I-131 treatment. These results are valuable in directing initial adjuvant therapy and follow-up intensity. Our results do not inform the question of the use of postoperative thyroglobulin (Tg) level to select N1b patients for low-dose I-131 treatment.

14.
J Neurooncol ; 157(3): 425-433, 2022 May.
Artículo en Inglés | MEDLINE | ID: mdl-35278157

RESUMEN

PURPOSE: To report disease control and treatment-related side effects among adult patients with craniopharyngioma treated with radiotherapy. METHODS: We performed a single-institution review of adult patients (> 21 years old) with craniopharyngioma treated with radiotherapy either definitively or postoperatively for gross residual disease. We report disease control, survival, and radiotherapy-related side effects. RESULTS: A total of 49 adult patients with craniopharyngioma were included, 27 of whom were treated at initial presentation and 22 for recurrent disease following initial surgery and observation. Overall, 77% received radiotherapy postoperatively (either after primary surgery or surgery for recurrence). With a median clinical and radiographic follow-up of 4.2 (range, 0.4-21.6) years and 3.0 (range, 0-21.5) years, the 5- and 10-year local control rates were 100 and 94%, respectively. The 5- and 10-year overall survival rates were 80 and 66%, respectively. Eleven percent of patients experienced grade 2 vision deterioration and 18% suffered grade 2 endocrinopathies following radiotherapy. CONCLUSIONS: Radiotherapy provides excellent disease control with acceptable toxicity among adult patients with craniopharyngioma. These data support the use of fractionated radiotherapy in adult patients with recurrent or gross residual disease after surgery. For inoperable patients or those with moderate or high surgical risk to neurologic and/or vascular structures, we advocate for limited surgical resection and postoperative radiotherapy to balance optimal tumor control with tumor- and treatment-related morbidity.


Asunto(s)
Craneofaringioma , Neoplasias Hipofisarias , Adulto , Craneofaringioma/radioterapia , Craneofaringioma/cirugía , Humanos , Recurrencia Local de Neoplasia/radioterapia , Recurrencia Local de Neoplasia/cirugía , Neoplasia Residual/cirugía , Neoplasias Hipofisarias/radioterapia , Neoplasias Hipofisarias/cirugía , Estudios Retrospectivos , Tasa de Supervivencia , Resultado del Tratamiento , Adulto Joven
15.
Pract Radiat Oncol ; 12(6): 496-503, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35219881

RESUMEN

Stereotactic body radiation therapy (SBRT) is commonly used to treat early-stage, node-negative primary lung cancer, but society guidelines provide limited information regarding several technical aspects of SBRT, leading to potential variation in practice. In this report, we present the technical details used by 3 academic institutions when treating a solitary primary lung tumor up to 5 cm in dimension with curative-intent SBRT. We provide specifications outlined in major active or recently completed clinical trials. Among the participating institutions, we discovered multiple divergences in treatment parameters, including, but not limited to, prescription dose and desired degree of heterogeneity within the target volume. It is unclear to what extent these differences in parameters might affect tumor control or toxicity, but updated consensus guidelines addressing the relevant SBRT prescription details may help standardize practice patterns.


Asunto(s)
Neoplasias Pulmonares , Radiocirugia , Humanos , Radiocirugia/métodos , Neoplasias Pulmonares/patología , Pulmón/patología , Consenso
16.
Cancer Invest ; 40(4): 348-353, 2022 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-35100059

RESUMEN

We evaluated outcomes in 131 patients with cutaneous melanoma (median follow-up, 3.6 years) considered at high risk of recurrence after surgery alone treated with surgery and postoperative radiotherapy. Eligible patients had one or more of the following: recurrence after surgery, positive lymph nodes, extracapsular extension, incomplete regional node dissection, microscopically positive margins, gross residual disease, or in-transit metastases. 102 patients received hypofractionated radiotherapy and 29 had conventional fractionation. 10-year outcomes were: in-field local-regional control, 87%; local regional control, 72%; distant metastasis-free survival, 48%; cause-specific survival, 44%; and overall survival, 31%. Three patients experienced acute toxicities while 6 experienced late toxicities.


Asunto(s)
Melanoma , Neoplasias Cutáneas , Fraccionamiento de la Dosis de Radiación , Humanos , Melanoma/patología , Melanoma/radioterapia , Melanoma/cirugía , Recurrencia Local de Neoplasia/patología , Radioterapia Adyuvante , Estudios Retrospectivos , Neoplasias Cutáneas/radioterapia , Neoplasias Cutáneas/cirugía
17.
Pract Radiat Oncol ; 12(1): 7-10, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-34670138

RESUMEN

Respected authors recommend broadening the radiation oncology (RO) scope-of-practice by taking more responsibility for the general medical care of our patients, directing the delivery of systemic cancer treatments that avoid the high toxicity of cytotoxic chemotherapy, managing palliative care, and supervising inpatient services for brachytherapy cases and problems related to radiation toxicity. The purpose of these changes is to increase RO involvement in clinical decision making and to avoiding becoming pigeon-holed as technicians instead of oncologists. There are no data estimating the financial implications of substituting traditional radiation oncology practice with that of an expanded clinical role. We sought to fill this void with a general proof-of-principle analysis based on current benchmark data. To determine the relative value units (RVU) of a blended radiation oncology practice, we selected the specialties of general internal medicine, hospital medicine, and palliative care as these fields most closely match the scope of the broadened clinical roles, which supporters of a more diversified radiation oncology practice typically advocate. To estimate the financial implications of a blended radiation oncology practice, we retrieved salary data by specialty and academic rank from the Clinical Practice Solutions Center report of annual RVU generation and the American Association of Medical Colleges annual faculty salary survey. For an assistant professor, this simulation estimates an 11% to 15% decrease in RVU generation for the median assistant professor operating with a 20% blended practice which, in turn, translates to a 7% to 9% decrease in total salary. The calculations for full professor demonstrate a similar decrease in total salary of approximately 8% to 9%.


Asunto(s)
Oncólogos , Oncología por Radiación , Cognición , Humanos , Salarios y Beneficios , Encuestas y Cuestionarios , Estados Unidos
18.
Otolaryngol Head Neck Surg ; 167(1): 100-108, 2022 07.
Artículo en Inglés | MEDLINE | ID: mdl-34546828

RESUMEN

OBJECTIVE: To compare survival outcomes between primary surgery and primary radiation therapy (RT) in patients with human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC). STUDY DESIGN: A retrospective observational cohort study. SETTING: National Cancer Database. METHODS: A National Cancer Database review was conducted of 2635 patients with HPV-negative OPSCC who underwent surgery or RT ± chemotherapy between 2010 and 2014. Univariate analysis was performed on all variables and entered into a multivariate model. The main outcome was overall survival (OS). RESULTS: A total of 2635 patients with HPV-negative OPSCC were organized into 4 groups based on cancer staging. In group 1 (T1-2 N0-1; n = 774), up-front surgery had significantly better 5-year OS (76.2%) than RT (56.8%; adjusted hazard ratio [aHR], 1.76; P = .009; 95% CI, 1.15-2.69) and chemoradiation therapy (CRT; 69.5%; aHR, 1.56; P = .019; 95% CI, 1.08-2.26). In group 2 (T3-4 N0-1; n = 327), no significant difference existed between surgery and CRT (5-year OS, 51.3% vs 52.4%; aHR, 0.96; P = .88; 95% CI, 0.54-1.69). In group 3a (T1-2 N2-3; n = 807), surgery with adjuvant treatment showed significantly better 5-year OS than CRT (78.6% vs 68.8%; aHR, 1.51; P = .027; 95% CI, 1.05-2.18). In group 3b (T3-4 N2-3; n = 737), surgery with adjuvant treatment was not statistically associated with better 5-year OS as compared with CRT (61.0% vs 43.7%; aHR, 1.53; P = .06; 95% CI, 0.98-2.39). CONCLUSION: Primary surgery may provide improved survival outcomes in many cases of HPV-negative OPSCCs. These data should be used in weighing treatment options and may serve as a basis to better delineate treatment algorithms for HPV-negative disease.


Asunto(s)
Alphapapillomavirus , Carcinoma de Células Escamosas , Neoplasias Orofaríngeas , Infecciones por Papillomavirus , Carcinoma de Células Escamosas/patología , Humanos , Neoplasias Orofaríngeas/patología , Papillomaviridae , Infecciones por Papillomavirus/complicaciones , Infecciones por Papillomavirus/patología , Infecciones por Papillomavirus/terapia , Estudios Retrospectivos , Análisis de Supervivencia
19.
Am J Clin Oncol ; 44(10): 533-535, 2021 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-34319915

RESUMEN

OBJECTIVES: Increasing the percentage of academic faculty who are female and/or an under-represented minority (URM) is a goal in radiation oncology. When studying diversity changes in our University Radiation Oncology Department, we found that increases in resident diversity preceded changes in faculty diversity in every major category. To illustrate these findings, we plotted resident versus faculty diversity each year over the 52-year history of our program. MATERIALS AND METHODS: Plots were generated of the percent of residents versus faculty in our program each year between 1967 and 2020 in the following categories: female, URM, and people of color. RESULTS: By 1995, substantial levels of diversity were present among both residents and faculty with approximate median annual values between 1995 and 2020 of 30% female for both residents and faculty, 15% URM for both residents and faculty, and 30% persons of color for residents and 15% for faculty. In all analyses, increase in resident diversity preceded an increase in faculty diversity and, in the great majority of years, resident diversity was greater than faculty diversity. CONCLUSION: Our experience suggests that it may be easier to increase resident than faculty diversity and that increases in resident diversity may facilitate increasing faculty diversity.


Asunto(s)
Docentes Médicos/estadística & datos numéricos , Internado y Residencia/estadística & datos numéricos , Grupos Minoritarios/estadística & datos numéricos , Oncología por Radiación , Femenino , Florida , Humanos , Masculino , Distribución por Sexo , Universidades
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...